Molecular diagnosis of the Portuguese founder mutation BRCA2 c.156-157insAlu

Breast Cancer Research and Treatment

Volumn 117, Issue 1, 2009, Pages 215-217

  Peixoto, Ana ^a   Santos, Catarina ^a   Rocha, Patrícia ^a   Pinto, Pedro ^a   Bizarro, Susana ^a   Teixeira, Manuel R ^a  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN;

EXON; GENE AMPLIFICATION; GENE INSERTION; GENE MUTATION; HUMAN; LETTER; NUCLEOTIDE SEQUENCE; PORTUGAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

BREAST NEOPLASMS; FEMALE; FOUNDER EFFECT; GENES, BRCA2; HUMANS; MUTATION; PORTUGAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 69049087994     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0214-z     Document Type: Letter

References (10)

1. Machado P, Vaz F (2008) Caution should be taken in the methodology used to confirm c.156-157insAlu BRCA2 mutation. Breast Cancer Res Treat (Epub ahead of print Jul 17, 2008). doi: 10.1007/s10549-008-0124-0
2. Peixoto A, Santos C, Rocha P et al (2008) The c.156-157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal. Breast Cancer Res Treat (Epub ahead of print Mar 25, 2008). doi: 10.1007/s10549-008-9978-4
3. E Teugels S De Brakeleer G Goelen 2005 De novo Alu element insertions targeted to a sequence common to the BRCA1 and BRCA2 genes Hum Mutat 26 284 10.1002/humu.9366
4. PM Machado RD Brandao BM Cavaco et al. 2007 Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes J Clin Oncol 25 2027 2034 10.1200/JCO.2006.06.9443
5. O Díez A Osorio M Durán et al. 2003 Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects Hum Mutat 22 301 312 10.1002/humu.10260
6. AH van der Hout AM van den Ouweland RB van der Luijt et al. 2006 A DGGE system for comprehensive mutation screening of BRCA1 and BRCA2: application in a Dutch cancer clinic setting Hum Mutat 27 654 666 10.1002/humu.20340
7. Human Genome Variation Society (HGVS). http://www.hgvs.org/
8. M Nordling P Karlsson J Wahlstrom et al. 1998 A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family Cancer Res 58 1372 1375
9. J Zou Y Hirose H Siddique et al. 1999 Structure and expression of variant BRCA2a lacking the transactivation domain Oncol Rep 6 437 440
10. C Bonnet S Krieger M Vezain et al. 2008 Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene J Med Genet 45 438 446 10.1136/jmg.2007.056895